Urigen Pharmaceuticals, Inc. and Hyaluron Contract Manufacturing (HCM) Enter into Drug Development Agreement for URG101

BURLINGAME, Calif.--(BUSINESS WIRE)--Urigen Pharmaceuticals, Inc. (OTCBB: URGP, http://www.urigen.com), a specialty pharmaceutical company focused on the development and commercialization of treatments for urological disorders, and Hyaluron Contract Manufacturing, Inc. (www.hyaluron.com), a leading provider of aseptic manufacturing services to companies in the pharmaceutical and biotechnology industries, have established a partnership to develop URG101, Urigen’s proprietary fixed dose combination of FDA-approved drugs targeting painful bladder syndrome (PBS).